Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

NCT07093606 | Recruiting

• 1 other identifier: Soh-Med--25-7-4MS
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Conditions

ITP - Immune Thrombocytopenia

Outcome Measures

Primary Outcomes (1)

• •To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

  the incidence and severity of liver dysfunction in ITP patients

  3-6 months after receiving eltombopag

Study Arms (1)

this group will receive Eltrombopag tabelts

EXPERIMENTAL

ITP patients in this group receive Eltrombopag then follow up by liver functions test to evulate occurance of liver disorders .

Drug: Eltrombopag

Interventions

Eltrombopag DRUG

ITP patients will receive Eltrombopag and evulate occurance of liver disordres .

this group will receive Eltrombopag tabelts

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may not qualify if:

• Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag university hospital

Sohag, Egypt

RECRUITING

Related Publications (3)

• Bidika E, Fayyaz H, Salib M, Memon AN, Gowda AS, Rallabhandi B, Cancarevic I. Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment. Cureus. 2020 Aug 21;12(8):e9920. doi: 10.7759/cureus.9920.

  PMID: 32968581 BACKGROUND

• Kuter DJ. New thrombopoietic growth factors. Blood. 2007 Jun 1;109(11):4607-16. doi: 10.1182/blood-2006-10-019315. Epub 2007 Feb 8.

  PMID: 17289815 BACKGROUND

• Ptushkin VV, Vinogradova OY, Pankrashkina MM, Chernikov MV, Arshanskaya EG, Tkachenko NE. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice. Ter Arkh. 2018 Aug 17;90(7):70-76. doi: 10.26442/terarkh201890770-76.

  PMID: 30701925 BACKGROUND

MeSH Terms

Conditions

Purpura, Thrombocytopenic, Idiopathic

Interventions

eltrombopag

Condition Hierarchy (Ancestors)

Purpura, Thrombocytopenic; Purpura; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Thrombotic Microangiopathies; Thrombocytopenia; Blood Platelet Disorders; Cytopenia; Hemorrhagic Disorders; Autoimmune Diseases; Immune System Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Skin Manifestations; Signs and Symptoms

Central Study Contacts

Peter A Alfy, Resident

CONTACT

01274069691; peter.adel.dola@gmail.com

Usama M Abdelaal, Professor

CONTACT

01065962094

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident , Internal medicine, Faculty of Medicine Sohag university

Study Record Dates

• First Submitted: July 23, 2025
• First Posted: July 30, 2025
• Study Start: July 14, 2025
• Primary Completion: January 20, 2026
• Study Completion: January 20, 2026
• Last Updated: July 30, 2025

Record last verified: 2025-07

Locations

EG (1)